Skip to main content

Advertisement

SpringerLink
Log in

New drugs under clinical evaluation in the United States

  • Short Review
  • New Drugs in USA
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ahmann, D. L., Hahn, R. G., Bisel, H. F. et al.: A phase II evaluation of ifosfamide (NSC-109724) treatment of disseminated breast cancer. Proc. Amer. Ass. Cancer Res. 15 (Abstr.), 182 (1974)

    Google Scholar 

  2. Anderson, T., McMenamin, M. G., Schein, P. S.: Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res. 35, 761–765 (1975)

    Google Scholar 

  3. Baker, B. R., Ashton, W. T.: Irreversible enzyme inhibitors. 196 active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimetyl-s-triazeno and bearing a terminal phenyl sulfonate group. J. med. Chem. 15, 945–947 (1972)

    Google Scholar 

  4. Bhuyan, B. K., Scheidt, L. G., Fraser, T. J.: Cell cycle phase specificity of antitumor agents. Cancer Res. 32, 398–407 (1972)

    Google Scholar 

  5. Bjornsson, S., Henderson, E. S.: Phase I trial of crystalline antibiotic. Proc. Amer. Ass. Cancer Res. 16 (Abstr.) 268 (1975)

    Google Scholar 

  6. Blokhina, N. G. et al.: Results of treatment of malignant tumors with Ftorafur. Cancer 30, 390–392 (1972)

    Google Scholar 

  7. Bradner, W. T., Hutchison, D. J.: Neocarzinostain (NSC-69856): an antitumor antibiotic effective against leukemia L1210 in mice. Cancer Chemother. Rep. 50, 79–84 (1966)

    Google Scholar 

  8. Brian, P. W., Dawkins, A. W., Grove, J. F. et al.: Phytotoxic compounds produced by Fusarium equiseti. J. exp. Bot. 12, 1–12 (1961)

    Google Scholar 

  9. Bruckner, H. W., Cohen, C. J., Gusberg, S. B. et al.: Chemotherapy of ovarian cancer with adriamycin (ADM) and cisplatinum (DDP) (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 17, 287 (1976)

    Google Scholar 

  10. Cohen, M. H., Mittelman, A.: Initial clinical trials with isofosfamide. Proc. Amer. Ass. Cancer Res. 14 (Abstr.), 64 (1973)

    Google Scholar 

  11. Csanyi, E., Halisz, M.: Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol (DBM)-resistant Yoshida s.c. sarcoma. Brit. J. Cancer 21, 353–357 (1967)

    Google Scholar 

  12. Cvitkovic, E., Wittes, R., Golbey, R. et al.: Primary combination chemotherapy (VAB II) for metastatic or unresectable germ cell tumors (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 16, 174 (1975)

    Google Scholar 

  13. Cvitkovic, E., Hayes, D., Golbey, R.: Primary combination chemotherapy (VAB II) for metastatic or unresectable germ cell tumors (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Sco. clin. Oncol. 17, 296 (1976)

    Google Scholar 

  14. Dawkins, A. W., Grove, J. F., Tidd, B. K.: Diacetoxyscirpenol and some related compounds. Chem. Commun. 2, 27 (1965)

    Google Scholar 

  15. Drewinko, B., Gottlieb, J. A.: Action of cis-dichlorodiammine-platinum (II) (NSC-119875) at the cellular level. Cancer Chemother. Rep. 59, 665–673 (1975)

    Google Scholar 

  16. Eagan, R. T., Frytak, S., Rubin, J.: Dianhydrogalactitol (DAG) vs. polychemotherapy in non-small cell lung cancer. Proc. Amr. Ass. Cancer Res. 17, 21 (1976a)

    Google Scholar 

  17. Eagan, R. T., Moertel, C. G., Hahn, R. G., Schutt, A. J.: Phase I study of a five-day intermittent schedule for DAG (NSC-132313). J. nat. Cancer Inst. 56 (1), 179–181 (1976)

    Google Scholar 

  18. Eckhardt, S., Sellei, C., Horvath, I. P., Institoris, L.: Effect of 1,6-dibromo-1,6-dideoxy-D-mannitol on chronic granulocytic leukemia. Cancer Chemother. Rep. 33, 57–61 (1963)

    Google Scholar 

  19. Eckhardt, S., Sellei, C., Institoris, L., Fenyes, G., Karika, S., Hartai, F.: Clinico-pharmacological investigations with myelobromol (DEM), pp. 267–271. III. Congr. Hung. Therap. Invest. Pharmacol., Budapest 1964

  20. Eckhardt, S.: Clinical pharmacology of dibromohexitols. X. International Cancer Congress, Houston 1970

  21. Einhorn, L., Donohue, J.: Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87, 293–298 (1977)

    Google Scholar 

  22. Flury, E., Mauli, R., Sigg, H. P.: The constitution of diacetoxyseirpenol. Chem. Commun. 2, 26 (1965)

    Google Scholar 

  23. Garibjanian, B., Kline, I., Vadlamudi, S., Golden, A.: Proc. Amer. Ass. Cancer Res. 15, 25 (1974)

    Google Scholar 

  24. Geran, R. I., Congleton, G. F., Dudeck, L. E., Abbott, B. J., Gargus, J. L.: A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemother. Rep. 4, 53–87 (1974)

    Google Scholar 

  25. Gottlieb, J. A., Freireich, E. J., Bodey, G. P. et al.: Preliminary clinical evaluation of piperazinedione (P), a new crystalline antibiotic. Proc. Amer. Ass. Cancer Res. 16 (Abstr.), 86 (1975)

    Google Scholar 

  26. Griffin, T., Comis, R. L., Lokich, J. et al.: Neocarzinostatin: Phase I study. Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 18, 302 (1977)

    Google Scholar 

  27. Haas, C. D., Stephens, R. L., Hollister, M., Hoogstraten, B.: Phase I evaluation of dianhydrogalactitol (NSC-132313). Cancer treat. Rep. 60 (5) 611–614 (1976)

    Google Scholar 

  28. Haas, C., Goodwin, C., Leite, R. et al.: Phase I study of anguidine. Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 18, 296 (1977)

    Google Scholar 

  29. Hartman, G. et al.: The specific inhibition of the DNA-directed RNA synthesis by rifamycin

  30. Hattori, T. et al.: Clinical experience with FT-207; with special reference to 5-fluorouracil. Jap. J. Cancer Clin. 19, 50–53 (1973)

    Google Scholar 

  31. Hayes, D., Cvitkovic, E., Golbey, R.: Amelioration of renal toxicity of high dose cis-platinum diammine dichloride (CPDD) by mannitol induced diuresis (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 17, 169 (1976)

    Google Scholar 

  32. Heere, L. J., Donnely, S. T.: Antitumor activity of hexamethylmelamine and imidazole carboxamide. Proc. Amer. Ass. Cancer Res. 12 (Abstr.), 101 (1971)

    Google Scholar 

  33. Hidvegi, E. J., Sebestyen, J., Szabo, L. D., Koteles, G. J., Institoris, L.: The effect of dibromodulcitol, diepoxydulcitol and various new cytostatic hexitil derivatives on the metabolic activities of nucleic acid and proteins. II. Biochem. Pharmacol. 25, 1705–1710 (1976)

    Google Scholar 

  34. Hidvegi, E., Lonai, P., Holland, J., Antoni, F., Institoris, L., Horvath, I. P.: The effect of mannitol myeleran and two new abromo hexitole on the metabolic activities of nucleic acids and proteins. I. Biochem. Pharmacol. 16, 2143–2153 (1967)

    Google Scholar 

  35. Higby, D. J., Wallace, H. J., Jr., Holland, J. F.: Cis-diammine-dichloroplatinum (NSC-119875): A phase I study. Cancer Chemother. Rep. 57, 459–463 (1973)

    Google Scholar 

  36. Higby, D. J., Wallace, H. J., Jr., Albert, D. et al.: Diamminodichloroplatinum in the chemotherapy of testicular tumors. J. Urol. 112, 100–104 (1974)

    Google Scholar 

  37. Higby, D. J., Wallace, H. J., Bekesi, J. G.: Reduction of cisdichlorodiammine platinum II (DDP) toxicity by penicillamine (Pn) compounds in animal models and humans (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 16, 131 (1975)

    Google Scholar 

  38. Hill, J. M., Loeb, E., MacLellan, A. et al.: Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother. Rep. 59, 647–659 (1975)

    Google Scholar 

  39. Horvath, I. P., Institoris, L.: 11, Part II. Mechanisms of Action 17, 149–155 (1967)

    Google Scholar 

  40. Institoris, L., Horvath, I. P., Csanyi, E.: Influence of the chemical structure on the biological tendency of cytostatic compounds related to dibromonmannitol. I. Structure activity correlations. Arzneimittel-Forsch. 17, 145–149 (1967a)

    Google Scholar 

  41. Institoris, L., Horvath, I. P., Pethes, G., Eckhardt, S.: Mechanisms of action of cytostatic dibromohexitols. Cancer Chemother. Rep. 51, 261–270 (1967b)

    Google Scholar 

  42. Ishida, N., Miyazaki, K., Kumagai, K., Rikimabu, M.: Neocarzinostatin, an antitumor antibiotic of high molecular weight. Isolation, physiochemical properties and biological activities. J. Antibiot. (Tokyo) 18, 68–76 (1965)

    Google Scholar 

  43. Ishida, N., Ishii, K., Kitajima, K., Hiraki, K., Kikuchi, M.: Clinical evaluation of antitumor protein Neocarzinostatin. Proc. of the 8th Internat. Congr. of Chemother., Progr. in Chemother. 3, 927 (1975)

    Google Scholar 

  44. Ishii, K., Nakamura, K.: Cooperative studies on the pancreatic cancer by Neocarzinostatin. Cancer and Chemother. (Japan) 1, 433 (1974)

    Google Scholar 

  45. Kaiser, D. W., Thurston, J. T., Dudley, J. R., Schaefer, F. C., Hechenbleikner, L., Holm-Harsen, D.: Cyanuric chloride derivatives. II. Substituted melamines. J. Amer. chem. Soc. 73, 2984–2986 (1951)

    Google Scholar 

  46. Karev, N. I. et al.: Experience with Ftorafur treatment in breast cancer. Neoplasma 19, 347–350 (1972)

    Google Scholar 

  47. Kaufman, J. H., Mittelman, A.: Phase I study of inosine dialdehyde (diglycoaldehyde NSC 118994). Proc. Amer. Ass. Cancer Res. 16 (Abstr.), 51 (1975)

    Google Scholar 

  48. Kellner, B.: 1,6-dibrommo-1,6-dideoxy-dulcitol: A new antitumor agent. Nature (Lond.) 213, 402–403 (1967)

    Google Scholar 

  49. Kitajima, K.: The clinical evaluation of a new antileukemia agent, Neocarzinostatin. Acta Haemat. jap. 37, 767–772 (1974)

    Google Scholar 

  50. Kovach, J. S., Moertel, C. G., Schutt, A. J. et al.: Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother. Rep. 57, 357–359 (1973)

    Google Scholar 

  51. Kumagai, K., Miyazaki, K.: The effect of carzinostatin on mouse ascitic leukemia SN-36. J. Antibiot. (Tokyo) 16, 55 (1963)

    Google Scholar 

  52. Kamagai, K., Ono, Y., Niskikawa, T., Ishida, N.: Cytological studies on the effect of Neocarzinostatin on HeLa cells. J. Antibiot. (Tokyo) 19, 69–74 (1966)

    Google Scholar 

  53. Kupchan, S. M. et al.: Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J. Amer. chem. Soc. 94, 1354–1356 (1972)

    Google Scholar 

  54. Lippman, A. J., Helson, C., Helson, L. et al.: Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother. Rep. 57, 191–200 (1973)

    Google Scholar 

  55. Loeb, E., Hill, J. M., MacLellan, A. et al.: Cis-platinum diamminodichloride in the treatment of squamous cell carcinoma and other malignant diseases. Wadley med. Bull. 5, 281–295 (1975)

    Google Scholar 

  56. Mansy, S., Rosenberg, B., Thomson, A. J.: Binding of cis-and trans-dichlorodiammineplatinum (II) to nucleosides. I. Location of the binding sites. J. Amer. chem. Soc. 95, 1633–1640 (1973)

    Google Scholar 

  57. Massaoka, T., Nakamura, H., Hasegawa, Y., Shibata, H., Tatsumi, N. et al.: Treatment of acute leukemia with Neocarzinostatin (NSC). Jap. J. clin. Hematol. 15, 1309–1319 (1974)

    Google Scholar 

  58. Meriren, D. V.: Belousova, A. K.: The mechanism of action of Ftorafur, a new antineoplastic agent. Vopr. Med. Khim. 18 (3), 253–293 (1972)

    Google Scholar 

  59. Merrin, C.: A new method to prevent toxicity with high doses of cis diammine platinum (therapeutic efficacy in previously treated widespread and recurrent testicular tumors) (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 17, 243 (1976)

    Google Scholar 

  60. Mizuno, S. et al.: Inhibition of DNA-dependent RNA polymerase reaction of Escherichia coli by an antimicrobial antibiotic, streptovaricin. Biochim. biophys. Acta (Amst.) 157, 322–332 (1968)

    Google Scholar 

  61. Munchausen, L. L.: The chemical and biological effects of cisdichlorodiammineplatinum (II), an antitumor agent, on DNA. Proc. nat. Acad. Sci. (Wash.) 71, 4519–4522 (1974)

    Google Scholar 

  62. Munchausen, L. L., Rahn, R. O.: Biologic and chemical effects of cis-dichlorodiammineplatinum (II) (NSC-119875) on DNA. Cancer Chemother. Rep. 59, 643–646 (1975)

    Google Scholar 

  63. Nemeth, L., Institoris, L., Somfai, S., Gal, F., Polyi, I., Sugar, J., Csuki, D., Szentirmey, Z., Kellner, B.: Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313). Cancer Chemother. Rep., Part I, 56, (5), 593–602 (1972)

    Google Scholar 

  64. Nishikawa, T., Kumagai, K., Kudo, A., Ishida, N.: Cytological study on the effect of Neocarzinostatin on sarcoma 180 in vivo. J. Antibiot. (Tokyo) 18, 223–227 (1965)

    Google Scholar 

  65. Nitschlke, R., Starling, K., Land, V. et al.: Cis-platinum (PDD) in childhood malignancies (abstract). Proc. Amer. Ass. Cancer Res., Proc. Amer. Soc. clin. Oncol. 17, 310 (1976)

    Google Scholar 

  66. Ohtsubo, K., Kaden, P., Mittermayer, C.: Polyribosomal breakdown in mouse fibroblasts (L-Cells) by fusarenon-X, a toxic principle isolated from Fusarium nivale. Biochim. biophys. Acta (Amst.) 287, 520–525 (1972)

    Google Scholar 

  67. Osieka, R., Bruntsch, U., Gailmeier, W. M. et al.: Cis-diaminodichloro-platin (II) in der Behandlung therapieresistenter maligner Hodenteratome. Dtsch. med. Wschr. 101, 191–195 (1976)

    Google Scholar 

  68. Otvos, L.: Stereochemistry of the reactions of biopolymers III alkylation of DNA with dibromodulcitol and analogous sugars. Chem. Abstr. 76, 109327 (g) (1972)

    Google Scholar 

  69. Piel, I. J., Perlia, C. P.: Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies. Cancer Chemother. Rep. 59, 995–999 (1975)

    Google Scholar 

  70. Piel, I. J., Meyer, D., Perlia, C. P. et al.: Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother. Rep. 58, 871–875 (1974)

    Google Scholar 

  71. Plants yield chemicals active against tumors. Chem. Engl. News 58–59 (Feb. 28, 1972)

  72. Pratt, C., Rivera, G., Shanks, E.: Phase I–II evaluation of piperazinedione in children with cancer. Proc. Amer. Ass. Cancer Res. 16 (Abstr.), 82 (1975)

    Google Scholar 

  73. Roberts, J. J., Pascoe, J. M.: Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds (letter). Nature (Lond.) 235, 282–284 (1972)

    Google Scholar 

  74. Rodriguez, V., Gottlieb, J. A., Burgess, M. A. et al.: Clinical studies of Baker's antifol (BAF). Proc. Amer. Ass. Cancer Res. 16 (Abstr.), 83 (1975)

    Google Scholar 

  75. Rosenberg, B., Van Camp, L., Krigas, T.: Inhibition of cell division in Escherichia coli by electrolysis products a platinum electrode (letter). Nature (Lond.) 205, 698–699 (1965)

    Google Scholar 

  76. Rosenberg, B.: Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 60, 399–406 (1973)

    Google Scholar 

  77. Sarma, D., Rajalakshmi, S.: Studies on the interaction of Neocarzinostatin with rat liver DNA in vivo and in vitro. Biochem. Pharmacol. 25, 789–792 (1976)

    Google Scholar 

  78. Schein, P. et al.: DNA synthesis by human bone marrow after incubation with BCNU or chlorozotocin (DNCU, NSC-178248). Proc. Amer. Ass. Cancer Res. 16, 122 (1976)

    Google Scholar 

  79. Skeel, R., Rodriguez, V., Freireich, E. J. et al.: Clinical and pharmacological studies of the folate antagonist, triazinate (Baker's antifol, TZT). Proc. Amer. Ass. Cancer Res. 15 (Abstr.), 77 (1974)

    Google Scholar 

  80. Skeel, R., Cashmer, A., Bertino, J.: Pre-clinical trials of a new triazine antifolate, NSC 139105. Proc. Amer. Ass. Cancer Res. 14 (Abstr.), 52 (1973)

    Google Scholar 

  81. Stolinsky, D. C., Bateman, J. R.: Further experience with hexamethylmelamine (NSC-13875) in the treatment of carcinoma of the cervix. Cancer Chemother. Rep. 57, 497–499 (1973)

    Google Scholar 

  82. Stone, P. J., Kelman, A. D., Sinex, F. M.: Specific binding of anti-tumor drug cis-Pt (NH3)2CI2 to DNA rich in guanine and cytosine (letter). Nature (Lond.) 251, 736–737 (1974)

    Google Scholar 

  83. Takahaski, M., Toriyama, K., Maeda, H., Kikuchi, M., Kumagai, K., Ishida, N.: Clinical trials of a new antitumor polypeptide: Neocarzinostatin (NSC). Tohoku J. exp. Med. 98, 273–280 (1969)

    Google Scholar 

  84. Takita, H., Didolkar, M. S.: Effect of hexamethylmelamine (NSC-13875) on small cell carcinoma of the lung (Phase II study). Cancer Chemother. Rep. 58, 371–374 (1974)

    Google Scholar 

  85. Talley, R. W., O'Bryan, R. M., Gutterman, J. U. et al.: Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875) — phase I clinical study. Cancer Chemother. Rep. 57, 465–471 (1973)

    Google Scholar 

  86. Tatsuno, T., Fujimoto, Y., Morita, Y.: Toxicological research on substances from Fusarium nivale III. The structure of nivalenol and its monacetate. Tetrahedron Lett. 2823 (1969)

  87. Tobey, R. A.: A simple, rapid technique for determination of the effects of chemotherapeutic agents on mammalian cellcycle traverse. Cancer Res. 32, 309–316 (1972)

    Google Scholar 

  88. Tobey, R. A., Crissman, H. A.: Unique techniques for cell cycle analysis utilizing mithramycin and flow microfluorometry. Exp. Cell Res. 93, 235–239 (1975)

    Google Scholar 

  89. Tobey, R. A., Oka, M. S., Crissman, H. A.: Differential effects of two chemotherapeutic agents, streptozotocin and chlorozotocin, on the mammalian cell cycle. Europ. J. Cancer 11, 433–441 (1975)

    Google Scholar 

  90. Vaidivieso, M., Bodey, G. P., McKelvey, E. M. et al.: Proc. Amer. Ass. Cancer Res. 16, 86 (1975)

    Google Scholar 

  91. Vaitkevicius, V. K., Baker, L. H., Burolar, T. R. et al.: Chemotherapy og gastrointestinal adenocarcinoma in cancer chemotherapy — Fundamental concepts and recent advances. Year book medical publisher

  92. Wampler, G. L., Mellette, S. J., Kumperminc, M., Regelson, W.: Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer. Cancer Chemother. Rep. 56, 505–514 (1972)

    Google Scholar 

  93. Wasserman, T. H., Comis, R. L., Handlesman, H., Penta, J. S., Slavik, M., Soper, W. T., Carter, S. K.: Tabular analysis of the clinical chemotherapy in solid tumors. Cancer Chemother. Rep. 36, 399–499 (1975)

    Google Scholar 

  94. Wiltshaw, E., Kroner, T.: Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer treat. Rep. 60, 55–60 (1976)

    Google Scholar 

  95. Wittes, R. E., Yagoda, A., Silvay, O. et al.: Chemotherapy of germ cell tumors of the testis. I. Induction of remissions with vinblastine, actinomycin D, and bleomycin. Cancer 37, 637–645 (1976)

    Google Scholar 

  96. Worzalla, J. F., Ramirez, G., Bryan, G. T.: N-demethylation of the antineoplastic agent hexamethylmelamine by rats and man. Cancer Res. 33, 2810–2815 (1973)

    Google Scholar 

  97. Worzalla, J. F., Kaiman, B. D., Johnson, B. M., Ramirez, G., Bryan, G. T.: Metabolism of hexamethylmelamine-ring C in rats and man. Cancer Res. 34, 2669–2674 (1974)

    Google Scholar 

  98. Worzalla, J. F., Kaiman, B. D., Johnson, B. M., Johnson, R. O., Bryan, G. T.: Biotransformations of a series of methylmelamine homologs of hexamethylmelamine. Proc. Amer. Ass. Cancer Res. 15 (Abstr.), 15 (1974)

    Google Scholar 

  99. Yang, S. S.: Rifamycin antibiotics: Inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts. J. nat. Cancer Inst. 49, 7–25 (1972)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern California Cancer Program, 1801 Page Mill Road, Bldg. B/Suite 200, 94304, Palo Alto, California, USA

    Stephen K. Carter

Authors
  1. Stephen K. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, S.K. New drugs under clinical evaluation in the United States. Cancer Chemother. Pharmacol. 1, 15–24 (1978). https://doi.org/10.1007/BF00253142

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00253142

Keywords

Search

Navigation